Another study by Asgari et al., showed that low levels of IL-2 cytokines were significantly associated with recurrence rate for HER-2(+)/ER(+) breast cancer regardless of the use of adjuvant therapy with tamoxifen and/or aromatase inhibitors. This evidence concerns the gene CYP19A1 and breast carcinoma.